Research. Advocacy. Support.

We advance ovarian cancer research while supporting women and their families.

Learn more about OCRFA

Know Your Risks

About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.

Learn about your risks

Risk Factors

Many factors can increase or decrease a woman's risk of developing ovarian cancer.

Increases Risk

  • Family history of breast, ovarian or colon cancer
  • Genetic mutations like BRCA
  • Post-menopausal
  • Increased age

Decreases Risk

  • Pregnancy
  • Breastfeeding
  • Use of oral contraceptives

Know the Symptoms

  • Bloating
  • Difficulty Eating
  • Pelvic / Abdominal Pain
  • Urinary Frequency

If these symptoms occur for more than 2 weeks and these symptoms are new or unusual for you, see a gynecologist and ask about ovarian cancer. Research shows that seeing a gynecologic oncologist for surgery and treatment significantly improves outcomes.

Share Your #OvarianStory

Every ovarian cancer survivor's voice has power. Hear Emily's story and use #OvarianStory to share your own.


Latest News

  • OCRFA Research Shows Novel Combination Therapy Effective in Ovarian Cancer

    (December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian cancer patients without BRCA mutations. The research was funded in part by an OCRFA grant to Rugang, Zhang, PhD. PARP inhibitors have already been approved… More

  • OCRFA’s Impact in 2017

    (December 14, 2017) For over two decades, you have made it possible for OCRFA to fund the most innovative and promising science, resulting in research breakthroughs that have advanced our understanding of ovarian cancer, how it starts and new treatment options, and you have enabled OCRFA to successfully advocate for federal research dollars and provide… More

  • The Relationship Between Cytotoxic CD8 Tumor-Infiltrating Lymphocytes and Overall Survival in High Grade Serous Ovarian Cancer

    (December 11, 2017) A study by the Ovarian Tumor Tissue Analysis Consortium, published in JAMA Oncology, looked at the association between cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) and overall survival with certain types of ovarian cancer. After an immunohistochemical analysis of 5,577 patients, researchers saw a strong correlation between high levels of CD8+ TILs and longer… More


Upcoming Events